MedTrace Logo

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

NCT00603668 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2021-08-16

No results posted yet for this study

Summary

This study will test different doses of anti-CD74 antibody in patients with NHL and/or CLL.

Conditions

  • Chronic Lymphocytic Lymphoma

Interventions

BIOLOGICAL

milatuzumab

two or three times a week dosing of hLL1 for a total of 4 weeks

Sponsors & Collaborators

Principal Investigators

  • William Wegener, MD, PhD · Gilead Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2013-01-31
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00603668 on ClinicalTrials.gov